


IF2

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
18861

In Re Application Of: **Louis Schofield**



Application No.
09/787,111

Filing Date
May 14, 2001

Examiner
Nita M. Minnifield

Customer No.
23389

Group Art Unit
1645

Confirmation No.
1473

Title:
IMMUNOGENIC COMPOSITIONS AND USES THEREOF

Address to:
**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.


37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
18861

In Re Application of: **Louis Schofield**



Application No. 09/787,111	Filing Date May 14, 2001	Examiner Nita M. Minnifield	Customer No. 23389	Group Art Unit 1645	Confirmation No. 1473
--------------------------------------	------------------------------------	---------------------------------------	------------------------------	-------------------------------	---------------------------------

Title:
IMMUNOGENIC COMPOSITIONS AND USES THEREOF

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)


Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail


I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

July 3, 2007
(Date)


Signature of Person Mailing Correspondence

Xiaochun Zhu
Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Signature

Dated: **July 3, 2007**

Xiaochun Zhu
Registration No. 56,311
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
516-742-4343

CC:



H:\work\536\18861\Amend\18861.ids.doc

3. Schenkman S. et al., "Glycophosphatidylinositol-anchored proteins in metacyclic trypomastigotes of *Trypanosoma cruzi*", *Molecular and Biochemical Parasitology* 29:141-152 (1988);
4. Galili U., "Evolution and pathophysiology of the human natural anti- α -galactosyl IgG (anti-Gal) antibody", *Sprigner Semin Immunopathol* 15:155-171 (1993);
5. German Patent Application No. DE4311580, published August 18, 1994 (with English Abstract); and
6. Dumitriu, S., "Polysaccharides In Medicinal Applications", Marcel Dekker, Inc. pages 277-291 (1996).

Applicant is submitting copies of the above-cited references together with copies of a Supplementary Partial European Search Report dated September 23, 2002, two European Office Actions dated July 22, 2003 and November 30, 2004, respectively, issued in the corresponding to European Patent Application No. 99945777.3, and two Australian Office Actions dated December 10, 2001 and September 29, 2004, respectively, issued in the corresponding Australian Patent No. 766837 (Application No. 58420/99).

Reference 1 was cited in the Supplementary Partial European Search Report and both of the European Office Actions, as well as the Australian Office Action dated September 29, 2004.

Reference 2 was cited in the Supplementary Partial European Search Report, and also in the European Office Action dated July 22, 2003.

Reference 3 was cited in the Supplementary Partial European Search Report.

Reference 4 was cited in the Australian Office Action dated December 10, 2001.

Reference 5 was cited in the European Office Action dated July 22, 2003.

Reference 6 was cited in the Australian Office Action dated December 10, 2001.

It is further respectfully submitted that the reference by Schofield L. et al., "CD1d-Restricted Immunoglobulin G Formation to GPI-Anchored Antigens Mediated by NKT Cells", *Science* 283(5399): 225-229 (1999), which was also cited in the Supplementary Partial European Search Report and the European Office Action dated July 22, 2003, was previously submitted in Applicant's Information Disclosure Statement dated August 9, 2002 and was also previously cited by the Examiner in the present application; therefore a copy of this reference is not provided.

In addition, Australian Patent Application AU-A-65674/94, which was cited in the European Office Action dated July 22, 2003 and in the Australian Office Action dated December 10, 2001, was previously submitted in Applicant's Information Disclosure Statement dated August 9, 2002; therefore a copy of this reference is not provided.

Moreover, the following references were cited in the Australian Office Action dated December 10, 2001, but were previously submitted in Applicant's Information Disclosure Statement dated August 9, 2002; therefore copies of these references are not provided:

Richardson M., et al., *Insect Molec. Biol.* 1(3): 139-147 (1993);

Gerold P., et al., *Mol. And Biochem. Parasit.* 175: 131-143 (1996);

Schofield L., et al., *Anal. Trop. Med. And Parasit* 87(6): 617-626 (1993);

Schofield L., et al., *Immun. And Cell Biol.* 74(6): 555-563 (1996);

Schofield L., et al., *J. Exp. Med.* 177(1): 145-153 (1993);

Tachado S., et al., *Proc. Nat. Acad. Sci USA*, 94: 4022-4027 (1997);

Schofield L., et al., *Braz. J. Med. And Biol. Res.* 27(2): 249-254 (1994);

McConville M., et al., *Biochem. J.* 294(9): 305-324 (1993);


Elhay M., et al., *Mol. And Biochem. Parasit.* 40(2): 255-268 (1990); and

Misek D., et al., *J. Biol. Chem* 267(23): 16266-16273 (1992).

Consideration of this Information Disclosure Statement is respectfully requested, since the art provided may be material to the examination of the present application as defined under 37 C.F.R. §1.56.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §§1.97(b), no statement or fee is required.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Xiaochun Zhu', written in a cursive style.

Xiaochun Zhu

Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343
XZ:ab

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)



Atty. Docket No. (Optional)

18861

Application Number

09/787,111

Applicant(s)

Louis Schofield

Filing Date

May 14, 2001

Group Art Unit

1645

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
1.	WO 97/10249	3/20/1997	PCT			Yes	
5.	DE 4311580	8/18/1994	Germany			Yes	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

2.	Romero G. et al., "Anti-inositolglycan antibodies selectively block some of the actions of insulin in intact BC ₃ H1 cells", <i>Proc. Natl. Acad. Sci. USA</i> 87:1476-1480 (1990)
3.	Schenkman S. et al., "Glycophosphatidylinositol-anchored proteins in metacyclic trypomastigotes of <i>Trypanosoma cruzi</i> ", <i>Molecular and Biochemical Parasitology</i> 29:141-152 (1988)
4	Galili U., "Evolution and pathophysiology of the human natural anti- α -galactosyl IgG (anti-Gal) antibody", <i>Sprigner Semin Immunopathol</i> 15:155-171 (1993)
6.	Dumitriu, S., "Polysaccharides In Medicinal Applications", Marcel Dekker, Inc. pages 277-291 (1996)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.